Celltrion Changes Late-Stage Trial Plans on Drug Copy

Celltrion Inc. postponed a late-stage trial of a biosimilar version of Roche Holding AG’s best-selling Rituxan drug, potentially benefiting competitors such as Boehringer Ingelheim GmbH and Novartis AG.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.